Clinical trials: Neuroendocrine Tumor Metastatic
Neuroendocrine Tumors
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Given the lack of other viable treatment options for metastatic neuroendocrine tumors, contrasted with our positive anecdotal experience, and the relative tolerability of the treatment regimen for colorectal cancer patients, we…
- Trial name
- NCT00398320
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Pamela L. Kunz
Melanoma
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
This study will be conducted with the aim of estimating the effectiveness, safety, patterns of use of nivolumab, and characteristics of patients with unresectable or metastatic melanoma, treated with nivolumab monotherapy in the…
- Trial name
- NCT03504696
- Testing
- Non-interventional
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Cancer, Melanoma
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
The study is a prospective phase II trial of radiation therapy concurrent with cisplatin chemotherapy in the treatment of locally advanced or metastatic melanoma in patients who are deemed to require radiation therapy by treating…
- Trial name
- NCT00707161
- Testing
- Radiation Therapy, Cisplatin, Surgical resection
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Utah
Cutaneous Melanoma, Nevi
miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation.
- Trial name
- NCT01444560
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Ruhr University of Bochum
Melanoma
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.
- Trial name
- NCT02905266
- Testing
- Nivolumab, Ipilimumab
- Where
- 16 sites in Australia, France and 2 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Cancer, Metastatic Melanoma
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
Background: A new cancer treatment involves collecting white blood cells from an individual, modifying them to secrete IL-2 and target the ESO-1 protein expressed on some cancers, and returning them to the body.
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
- Trial name
- NCT01457131
- Testing
- Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard…
- Trial name
- NCT07086105
- Testing
- Adze1.C
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Adze Biotechnology Australia Pty Ltd
Metastatic Uveal Melanoma
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to Tebentafusp (better efficacy of anti-PD-1 after Tebentafusp), the combination of pembrolizumab and lenvatinib…
- Trial name
- PLUME (NCT05282901)
- Testing
- Pembrolizumab 25 MG/1 ML Intravenous Solution
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Institut Curie
Head and Neck Cancer
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100828
- Testing
- irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma (Skin)
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral…
- Trial name
- NCT00037037
- Testing
- MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Metastatic Malignant Melanoma
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
This multicenter, retrospective observational study aims to identify clinical, pathological, and molecular factors associated with prognosis and treatment response in patients with metastatic malignant melanoma.
- Trial name
- MEL-CARE (NCT07256184)
- Testing
- Systemic Therapy for Metastatic Melanoma
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 232 people
- Sponsor
- Ankara Etlik City Hospital
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma
- Trial name
- NCT02721732
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Malignant Melanoma
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Background: Most therapeutic therapies for metastatic melanoma have focused on the ability of T-cell lymphocytes to kill cells of tumors.
- Conditions
- Melanoma, Malignant Melanoma, Melanoma, Experimental, Experimental Melanomas
- Trial name
- NCT00513604
- Testing
- aldesleukin, therapeutic autologous lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox
This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox.
- Trial name
- NCT02009384
- Testing
- Ipilimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Louisville
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479…
- Trial name
- NCT01562899
- Testing
- MEK162, AMG 479
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Melanoma
A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
Considerable progress in the treatment of metastatic melanoma has been made in the past 5years, with the approval of immune checkpoint-blocking antibodies and agents targeting BRAF mutation.
- Trial name
- NCT02619058
- Testing
- NKT cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Malignant Melanoma
ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma
With the introduction of checkpoint inhibitors substantial improvements have been made in the treatment of malignant melanoma (MM). Despite this still a a subset of patients, approximately 50 %, experience no response to therapy.
- Trial name
- NCT04904185
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Multiple Antigen Specific Endogenously derived T cells
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Inge Marie Svane
Cancer, Malignancy
A Study of ASN007 in Patients With Advanced Solid Tumors
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups.
- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm
- Trial name
- NCT03415126
- Testing
- ASN007: ascending doses, ASN007 RD
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Asana BioSciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.